Citations

Showing 10 of 108094 citations.

Pediatric Electrophysiology Device Needs: A Survey from the Pediatric and Congenital Electrophysiology Society Taskforce on Pediatric‐Specific Devices
Dubin, Anne M. , Bar‐Cohen, Yaniv , Berul, Charles I. , Cannon, Bryan C. , Saarel, Elizabeth V. , Shah, Maully J. , Triedman, John K. , Saarel, Elizabeth V , Dubin, Anne M

Mayo Clinic

Journal of the American Heart Association | November 3, 2022 | Volume: 11 | Issue: 22 | Pages: No page available

10.1161/jaha.122.026904 | PMID 36326051 Get It

Background There are few US Food and Drug Administration (FDA)–approved devices specifically aimed at the pediatric patient with arrhythmia. This has led to a high off‐label utilization of devices in this vulnerable population. The Pediatric and Congenital Electrophysiology Society (PACES), the international organization representing pediatric and congenital heart disease arrhythmia specialists, developed a task force to comprehensively address device development issues relevant to pediatric patients with congenital arrhythmia. Methods and Results As a first step, the taskforce developed a 26‐question survey for the pediatric arrhythmia community to assess providers’ understanding of the FDA approval process, specifically in regard to pediatric labeling. There were 92/211 respondents (44%) with a >90% completion rate. The vast majority of respondents believed there was a paucity of devices available for children (96%). More than 60% of respondents stated that they did not understand the FDA regulatory process and were not aware of whether the devices they used were labeled for pediatric use. Conclusions Pediatric electrophysiologists are keenly aware of the deficit of available pediatric devices for their patients. The majority do not understand the FDA approval process and could benefit from additional educational resources regarding this. A collaborative forum including PACES, FDA, patients and their families, and Industry would be an important next step in clarifying opportunities and priorities to serve this vulnerable population.
Multisite analysis of patient experience scores and risk of hospital admission: a retrospective cohort study
Hydoub, Yousif M. , Fischer, Karen M. , Hanson, Kristine T. , Coons, Trevor J. , Wilshusen, Laurie , Vista, Tafi L. , Colbenson, Gretchen A. , Burton, M. Caroline , Habermann, Elizabeth B. , Dugani, Sagar B. , Wilshusen, Laurie L , Habermann, Elizabeth , Hydoub, Yousif M , Fischer, Karen M , Coons, Trevor , Dugani, Sagar B , Hanson, Kristine

Mayo Clinic

Hospital Practice | November 3, 2022 | Volume: 51 | Issue: 1 | Pages: 35-43

10.1080/21548331.2022.2144055 | PMID 36326005 Get It

The impact of preservation and recovery of renal function on survival after veno‐arterial extracorporeal life support: A retrospective cohort study
Prasad, Amit , Singbartl, Kai , Singbartl, Kai , Brehm, Christoph

Mayo Clinic

Artificial Organs | November 3, 2022 | Volume: 47 | Issue: 3 | Pages: 554-565

10.1111/aor.14449 | PMID 36325712 Get It

AbstractBackgroundVeno‐arterial extracorporeal life support (V‐A ECLS) has become a cornerstone in the management of critical cardiogenic shock, but it can also precipitate organ injury, e.g., acute kidney injury (AKI). Available studies highlight the effect of non‐cardiac organ injury on patient outcomes. Only very little is known about the impact of non‐cardiac organ recovery on patient survival. AKI occurs frequently during cardiogenic shock and carries a poor prognosis. We have developed descriptive models to hypothesize on the role of AKI severity versus that of recovery of renal function for patient survival.MethodsRetrospective, observational study including 175 patients who were successfully decannulated from V‐A ECLS. We assessed AKI severity using the “Kidney Disease: Improving Global Outcomes” (KDIGO) criteria. We defined recovered or preserved renal function (RPRF) prior to decannulation from V‐A ECLS as 0 (AKI with no improvement) or 1 (no AKI or AKI with improvement). We classified patient outcomes as alive or dead at hospital discharge.Results78% (n = 138) of all patients survived hospital discharge of which 38% (n = 67) never developed AKI. After adjusting for shock severity and non‐renal organ injury, RPRF emerged as an independent predictor of survival in both the overall cohort [OR (95% CI) – 4.11 (1.72–9.79)] and the AKI‐only sub‐cohort [OR (95% CI) – 5.18 (1.8–14.92)]. Neither maximum KDIGO stage nor KDIGO stage at the end of V‐A ECLS was independently associated with survival.ConclusionsOur model identifies RPRF, but not AKI severity, as an independent predictor of hospital survival in patients undergoing V‐A ECLS for cardiogenic shock. We hypothesize that recovered or preserved non‐cardiac organ function during V‐A ECLS is crucial for patient survival.
Strategies for equity‐driven practice advancement in dermatology
Handfield, Chelsea , Anderson, Katelyn , Wyles, Saranya P. , Wyles, Saranya

Mayo Clinic

International Journal of Dermatology | November 3, 2022 | Volume: 62 | Issue: 8 | Pages: 1094-1095

10.1111/ijd.16483 | PMID 36324282 Get It

Outpatient visit modality and parallel patient satisfaction: A multi-site cohort analysis of telemedicine and in-person visits during the COVID-19 pandemic
Ploog, Nicole J, Coffey, Jordan , Wilshusen, Laurie , Coffey, Jordan D , Ploog, Nicole, Demaerschalk, Bart M.

Mayo Clinic

Patient Experience Journal | November 3, 2022 | Volume: 9 | Issue: 3 | Pages: 93-101

10.35680/2372-0247.1704 Get It

Telemedicine approaches provide many benefits to patients across both primary and specialty care. Patient acceptance is imperative to successful telemedicine implementation. As telemedicine utilization continues to surge, it is imperative that healthcare organizations have a method for evaluating the patient experience with these types of visits. Previous studies on experience with telemedicine have focused on smaller patient populations with narrow inclusion criteria and limited geographical reach. This research described how patients’ satisfaction with video telemedicine-based visits varied based on patient characteristics and how they compare with in-person visits. We obtained and analyzed results from standardized patient experience surveys to compare telemedicine and in-person clinic visits during the COVID-19 pandemic (between July 1, 2020, and June 30, 2021) across a diverse patient population. During the study timeframe, surveys were sent to 1,521,398 patients with a response rate of 20% (307,185). Our organization’s unique structure, size, and geographic spread allowed for a deeper and more comprehensive examination of telemedicine participants. Though a few trends emerged in the results, there were no significant differences in patient ratings of telemedicine visits and in-person clinic visits during the same period (p=0.672). This study demonstrated that patient satisfaction with telemedicine visits was non-inferior to in-person outpatient visits during the study timeframe. Experience Framework This article is associated with the Innovation & Technology lens of The Beryl Institute Experience Framework (https://www.theberylinstitute.org/ExperienceFramework). Access other PXJ articles related to this lens. Access other resources related to this lens
Enhancing Immunogenicity of Influenza Vaccine in the Elderly through Intradermal Vaccination: A Literature Analysis
Kennedy, Richard B. , Quach, Huy Quang , Kennedy, Richard

Mayo Clinic

Viruses | November 3, 2022 | Volume: 14 | Issue: 11 | Pages: 2438

10.3390/v14112438 | PMID 36366536 Get It

Background: Aging and immunosenescence lead to a gradual decline in immune responses in the elderly and the immunogenicity of influenza vaccines in this age group is sub-optimal. Several approaches have been explored to enhance the immunogenicity of influenza vaccines in the elderly, including incorporating vaccine adjuvant, increasing antigen dosage, and changing the route of vaccine administration. Method: We systematically compared the immunogenicity and safety of influenza vaccines administered by intradermal (ID) route and either intramuscular (IM) or subcutaneous (SC) routes in older adults aged ≥ 65. Results: Of 17 studies included in this analysis, 3 studies compared the immunogenicity of ID vaccination to that of SC vaccination and 14 studies compared ID and IM vaccinations. ID vaccination was typically more immunogenic than both IM and SC routes at the same dosage. Importantly, a minimum of 3 µg of hemagglutinin antigen could be formulated in an ID influenza vaccine without a significant loss of immunogenicity. ID administration of standard-dose, unadjuvanted influenza vaccine was as immunogenic as IM injection of adjuvanted influenza vaccine. Waning of influenza-specific immunity was significant after 6 months, but there was no difference in waning immunity between vaccinations in ID, IM, or SC routes. While ID vaccination elicited local adverse reactions more frequently than other routes, these reactions were mild and lasted for no more than 3 days. Conclusions: We conclude that ID vaccination is superior to IM or SC routes and may be a suitable approach to compensate for the reduced immunogenicity observed in elderly adults. We also conclude that the main benefit of ID influenza vaccine lies in its dose-sparing effect. Additional research is still needed to further develop a more immunogenic ID influenza vaccine.
Preclinical Experience of the Mayo Spheroid Reservoir Bioartificial Liver (SRBAL) in Management of Acute Liver Failure
Felgendreff, Philipp , Tharwat, Mohammad , Hosseiniasl, Seyed M. , Amiot, Bruce , Minshew, Anna, Rmilah, Anan Abu , Sun, Xiaoye, Duffy, Dustin, Kremers, Walter K. , Nyberg, Scott L. , Nyberg, Scott L , Kremers, Walter K

Mayo Clinic

Livers | November 3, 2022 | Volume: 2 | Issue: 4 | Pages: 387-399

10.3390/livers2040029 Get It

The Spheroid Reservoir Bioartificial Liver (SRBAL) is an innovative treatment option for acute liver failure (ALF). This extracorporeal support device, which provides detoxification and other liver functions using high-density culture of porcine hepatocyte spheroids, has been reported in three randomized large animal studies. A meta-analysis of these three preclinical studies was performed to establish efficacy of SRBAL treatment in terms of survival benefit and neuroprotective effect. The studies included two hepatotoxic drug models of ALF (D-galactosamine, α-amanitin/lipopolysaccharide) or a liver resection model (85% hepatectomy) in pigs or monkeys. The SRBAL treatment was started in three different settings starting at 12 h, 24 h or 48 h after induction of ALF; comparisons were made with two similar control groups in each model. SRBAL therapy was associated with significant survival and neuroprotective benefits in all three animal models of ALF. The benefits of therapy were dose dependent with the most effective configuration of SRBAL being continuous treatment of 24 h duration and dose of 200 g of porcine hepatic spheroids. Future clinical testing of SRBAL in patients with ALF appears warranted.
Natural Killer Cells Are Key Host Immune Effector Cells Affecting Survival in Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation
Porrata, Luis F.

Mayo Clinic

Cells | November 3, 2022 | Volume: 11 | Issue: 21 | Pages: 3469

10.3390/cells11213469 | PMID 36359863 Get It

The infusion of autograft immune effector cells directly impacts the clinical outcomes of patients treated with autologous peripheral blood hematopoietic stem cell transplantation, suggesting the possibility of an autologous graft-versus tumor cells. Furthermore, the early recovery of immune effector cells also affects survival post-autologous peripheral blood hematopoietic stem cell transplantation. Natural killer cells are among the immune effector cells reported to be collected, infused, and recovered early post-autologous peripheral blood hematopoietic stem cell transplantation. In this review, I attempt to give an update on the role of natural killer cells regarding improving survival outcomes on patients treated with autologous peripheral blood hematopoietic stem cell transplantation.
Melatonin Treatment Triggers Metabolic and Intracellular pH Imbalance in Glioblastoma
Fernández-Gil, Beatriz I. , Otamendi-Lopez, Andrea, Bechtle, Alexandra , Vazquez-Ramos, Carla , Qosja, Neda, Suárez-Meade, Paola , Jentoft, Mark E. , Guerrero‐Cazares, Hugo , Escames, Germaine , Quiñones‐Hinojosa, Alfredo , Vazquez-Ramos, Carla A, Guerrero-Cazares, Hugo , Escames, Germaine , Schiapparelli, Paula , Sarabia-Estrada, Rachel

Mayo Clinic

Cells | November 3, 2022 | Volume: 11 | Issue: 21 | Pages: 3467

10.3390/cells11213467 | PMID 36359862 Get It

Metabolic rewiring in glioblastoma (GBM) is linked to intra- and extracellular pH regulation. In this study, we sought to characterize the role of melatonin on intracellular pH modulation and metabolic consequences to identify the mechanisms of action underlying melatonin oncostatic effects on GBM tumor initiating cells. GBM tumor initiating cells were treated at different times with melatonin (1.5 and 3.0 mM). We analyzed melatonin’s functional effects on GBM proliferation, cell cycle, viability, stemness, and chemo-radiosensitivity. We then assessed the effects of melatonin on GBM metabolism by analyzing the mitochondrial and glycolytic parameters. We also measured the intracellular and extracellular pH. Finally, we tested the effects of melatonin on a mouse subcutaneous xenograft model. We found that melatonin downregulated LDHA and MCT4, decreasing lactate production and inducing a decrease in intracellular pH that was associated with an increase in ROS and ATP depletion. These changes blocked cell cycle progression and induced cellular death and we observed similar results in vivo. Melatonin’s cytotoxic effects on GBM were due, at least in part, to intracellular pH modulation, which has emerged as a newly identified mechanism, providing new insights into the oncostatic effect of melatonin on GBM.
A novel through-the-scope helix tack-and-suture device for mucosal defect closure following colorectal endoscopic submucosal dissection: a multicenter study
Farha, Jad , Ramberan, Hemchand, Aihara, Hiroyuki , Zhang, Linda Y. , Mehta, Amit , Hage, Camille , Schlachterman, Alexander , Kumar, Anand , Shinn, Brianna , Canakis, Andrew , Kim, Raymond E., Buscaglia, Jonathan M. , Samarasena, Jason , Chang, Kenneth J. , Friedland, Shai , Qumseya, Bashar , Jawaid, Salmaan , Othman, Mohamed O. , Hasan, Muhammad K. , Khashab, Mouen A., Ngamruengphong, Saowanee , group, ESD-Closure working, Storm, Andrew C , Othman, Mohamed O , Canakis, Andrew , D'Souza, Lionel S. , Storm, Andrew C. , Draganov, Peter V. , Yang, Dennis J. , Khashab, Mouen A. , group, ESD-Closure working

Mayo Clinic

Endoscopy | November 3, 2022 | Volume: 55 | Issue: 06 | Pages: 571-577

10.1055/a-1970-5528 | PMID 36323330 Get It

Background Complete closure of large mucosal defects following colorectal endoscopic submucosal dissection (ESD) with through-the-scope (TTS) clips is oftentimes not possible. We aimed to report our early experience of using a novel TTS suturing system for the closure of large mucosal defects after colorectal ESD. Methods We performed a retrospective multicenter cohort study of consecutive patients who underwent attempted prophylactic defect closure using the TTS suturing system after colorectal ESD. The primary outcome was technical success in achieving complete defect closure, defined as a < 5 mm residual mucosal defect in the closure line using TTS suturing, with or without adjuvant TTS clips. Results 82 patients with a median defect size of 30 (interquartile range 25–40) mm were included. Technical success was achieved in 92.7 % (n = 76): TTS suturing only in 44 patients (53.7 %) and a combination of TTS suturing to approximate the widest segment followed by complete closure with TTS clips in 32 (39.0 %). Incomplete/partial closure, failure of appropriate TTS suture deployment, and the need for over-the-scope salvage closure methods were observed in 7.3 % (n = 6). One intraprocedural bleed, one delayed bleed, and three intraprocedural perforations were observed. There were no adverse events related to placement of the TTS suture. Conclusion The TTS suture system is an effective and safe tool for the closure of large mucosal defects after colorectal ESD and is an alternative when complete closure with TTS clips alone is not possible.